Benitec Biopharma Inc. (BNTC) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Hayward, CA, United States. The current CEO is Jerel A. Banks.
BNTC has IPO date of 2014-06-24, 16 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $347.77M.
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
